MUSOLINO, Antonino

MUSOLINO, Antonino  

Dipartimento di Medicina e Chirurgia  

Mostra records
Risultati 1 - 20 di 152 (tempo di esecuzione: 0.017 secondi).
Titolo Data di pubblicazione Autore(i) File
1134 POSTER Survival prediction of terminally ill cancer patients by clinical and laboratory parameters: usefullness role of simple prognostic indicators 1-gen-2007 Vasini, G.; Bacchini, G. P.; Franciosi, V.; Ghidini, C.; Musolino, A.; Camisa, R.; Meschi, Tiziana; Borghi, Loris; Ardizzoni, A.
20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years 1-gen-2017 Pan, H.; Gray, R.; Braybrooke, J.; Davies, C.; Taylor, C.; Mcgale, P.; Peto, R.; Pritchard, K. I.; Musolino, A.; Bergh, J.; Dowsett, M.; Hayes, D. F.
522 POSTER Immunoglobulin G fragment C receptor polymorphisms and clinical outcome of EGFR-expressing metastatic colorectal cancer patients treated with cetuximab-based therapy 1-gen-2007 Negri, F.; Musolino, A.; Naldi, N.; Bortesi, B.; Boni, C.; Bisagni, G.; Camisa, R.; Ardizzoni, A.
[68Ga]Nivolumab: a novel PET tracer to detect PD-1 expressing tumors 1-gen-2017 Migliari, S; Sammartano, A; Pellegrino, B; Regina, V; Cavazzini, D; Ottonello, S; Missale, G; Musolino, A; Ruffini, L
9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio 1-gen-2018 Conte, P. F.; Guarneri, V.; Bisagni, G.; Piacentini, F.; Brandes, A. A.; Cavanna, L.; Giotta, F.; Aieta, M.; Gebbia, V.; Frassoldati, A.; Musolino, A.; Garrone, O.; Taverniti, C.; Rimanti, A.; Sarti, S.; Rubino, D.; Bologna, A.; Vicini, R.; Balduzzi, S.; D'Amico, R.
9 Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study ShortHER 1-gen-2010 Guarneri, ; V, (Guarneri; V., ); Frassoldati; A, (Frassoldati; A., ); Gebbia; V, (Gebbia; V., ); Bisagni; G, (Bisagni; G., ); Cavanna; L, (Cavanna; L., ); Donadio; M (Donadio, ; M., ); Lelli; G, (Lelli; G., ); Musolino, A; Colucci, ; G, (Colucci; G., ); Banna; Gl, (Banna; G. L., ); Esposti; Rd, (Esposti; R., Degli); Ferro; A, (Ferro; A., ); Grasso; F, (Grasso; F., ); Zamagni; C, (Zamagni; C., ); Amadori; D, (Amadori; D., ); Aieta; M, (Aieta; M., ); Molino; A, (Molino; A., ); Garrone; O, (Garrone; O., ); Aitini; E (Aitini, ; E., ); Fornari; G, (Fornari; G., ); Cascinu; S, (Cascinu; S., ); Rossi; G, (Rossi; G., ); D'Amico; R, (D'Amico; R., ); Conte; Pf, (Conte; P. F., )
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER 1-gen-2017 Conte, Pier Franco; Bisagni, Giancarlo; Frassoldati, Antonio; Brandes, Alba Ariela; Anselmi, Elisa; Giotta, Francesco; Aieta, Michele; Gebbia, Vittorio; Musolino, Antonino; Garrone, Ornella; Taverniti, Cristiana; Cavazzini, Giovanna; Turletti, Anna; Rubino, Daniela; Picardo, Elisa; Ferro, Antonella; Piacentini, Federico; Balduzzi, Sara; D'Amico, Roberto; Guarneri, Valentina
Abstract OT1-03-03: Phase II, open label, randomized, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with operable or locally advanced/Inflammatory HER2-positive breast cancer. ImmunHER trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 1-gen-2018 Musolino, A; Gori, S; Cavanna, L; Graiff, C; Frassoldati, A; Bria, E; Bisagni, G; Zambelli, A; Partesotti, G; Brandes, A; Bonetti, A; Moscetti, L; Zamagni, C; Rocca, A; Generali, D; Montemurro, F; Gianni, L; Tognetto, M; Maglietta, G; Todeschini, R
Abstract P1-14-05: Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE Trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 1-gen-2019 Musolino, A; Cavanna, L; Boggiani, D; Zamagni, C; Frassoldati, A; Caldara, A; Rocca, A; Gori, S; Piacentini, F; Berardi, R; Brandes, Aa; Foglietta, J; Villa, F; Pellegrino, B; Todeschini, R; Tognetto, M; Naldi, N; Bortesi, B; Boni, L; Montemurro, F; Ardizzoni, A
Accuracy and relative value of bone marrow aspiration in the detection of lymphoid infiltration in non-Hodgkin lymphoma 1-gen-2010 Musolino, A; Guazzi, A; Nizzoli, R; Panebianco, M; Mancini, C; Ardizzoni, A
ACTIVITY AND SAFETY OF DOSEADJUSTED INFUSIONAL CHOP CHEMOTHERAPY WITH RITUXIMAB (DAPOCHR) IN VERY ELDERLY PATIENTS WITH POORPROGNOSTIC UNTREATED DIFFUSE LARGE BCELL NONHODGKIN'S LYMPHOMA 1-gen-2010 Boggiani, ; D, (Boggiani; D., ); Musolino, A; Panebianco, ; M, (Panebianco; M., ); Franciosi; V, (Franciosi; V., ); Vasini; G, (Vasini; G., ); Salvagni; S (Salvagni, ; S., ); Ardizzoni; A, (Ardizzoni; A., )
Activity and Safety of DoseAdjusted Infusional Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Chemotherapy With Rituximab in Very Elderly Patients With PoorPrognostic Untreated Diffuse Large B Cell Non Hodgkin Lymphoma 1-gen-2011 Musolino, A; Boggiani, ; D, (Boggiani; Daniela);, Panebianco; M, (Panebianco; Michele);, Vasini; G, (Vasini; Giovanna);, Salvagni; S (Salvagni, ; Stefania);, Franciosi; V, (Franciosi; Vittorio);, Ardizzoni; A, (Ardizzoni; Andrea),
Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient 1-gen-2017 Pellegrino, B.; Musolino, A.; Tiseo, M.
Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force 1-gen-2022 Razis, E; Escudero, M J; Palmieri, C; Mueller, V; Bartsch, R; Rossi, G; Gampenrieder, S P; Kolberg, H C; Zdenkowski, N; Pavic, M; Connolly, R M; Rosset, L; Arcuri, J; Tesch, H; Vallejos, C; Retamales, J; Musolino, A; Del Mastro, L; Christodoulou, C; Aebi, S; Paluch-Shimon, S; Gupta, S; Ohno, S; Macpherson, I; Ekholm, M; Zaman, K; Vidal, M; Chakiba, C; Fumagalli, D; Thulin, A; Witzel, I; Kotecki, N; Gil-Gil, M; Linderholm, B
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer 1-gen-2019 Dieci, M. V.; Conte, P.; Bisagni, G.; Brandes, A. A.; Frassoldati, A.; Cavanna, L.; Musolino, A.; Giotta, F.; Rimanti, A.; Garrone, O.; Bertone, E.; Cagossi, K.; Sarti, S.; Ferro, A.; Piacentini, F.; Maiorana, A.; Orvieto, E.; Sanders, M.; Miglietta, F.; Balduzzi, S.; D'Amico, R.; Guarneri, V.
Biological Role and Clinical Implications of microRNAs in BRCA Mutation Carriers 1-gen-2021 Tommasi, Chiara; Pellegrino, Benedetta; Boggiani, Daniela; Sikokis, Angelica; Michiara, Maria; Uliana, Vera; Bortesi, Beatrice; Bonatti, Francesco; Mozzoni, Paola; Pinelli, Silvana; Squadrilli, Anna; Viani, Maria Vittoria; Cassi, Diana; Maglietta, Giuseppe; Meleti, Marco; Musolino, Antonino
BOLERO-3 results: Pharmacological activity or pharmacokinetic effect? 1-gen-2014 Buti, S.; Bersanelli, M.; Tiseo, M.; Ardizzoni, A.; Musolino, A.
Brain metastasis (BM) prediction by transcriptomic profiling in triple-negative breast cancer (TNBC) 1-gen-2016 Duchnowska, Renata; Jarzab, Michal; Zebracka, Jadwiga; Matkowski, Rafal; Kowalczyk, Anna; Radecka, Barbara; Foszczynska-Kloda, Malgorzata; Musolino, Antonino; Czartoryska-Arlukowicz, Bogumila; Litwiniuk, Maria Malgorzata; Szablowska-Siwik, Sylwia; Karczmarek-Borowska, Bozenna; Sosinska-Mielcarek, Katarzyna; Chmielowska, Ewa; Olszewski, Wojciech P; Patera, Janusz; Zawrocki, Anton; Rusinek, Dagmara; Jassem, Jacek; Biernat, Wojciech
Brain Metastasis Prediction by Transcriptomic Profiling in Triple-Negative Breast Cancer 1-gen-2016 Duchnowska, R; Jarząb, M; Żebracka-Gala, J; Matkowski, R; Kowalczyk, A; Radecka, B; Kowalska, M; Pfeifer, A; Foszczyńska-Kłoda, M; Musolino, A; Czartoryska-Arłukowicz, B; Litwiniuk, M; Surus-Hyla, A; Szabłowska-Siwik, S; Karczmarek-Borowska, B; Dębska-Szmich, S; Głodek-Sutek, B; Sosińska-Mielcarek, K; Chmielowska, E; Kalinka-Warzocha, E; Olszewski, Wp; Patera, J; Żawrocki, A; Pliszka, A; Tyszkiewicz, T; Rusinek, D; Oczko-Wojciechowska, M; Jassem, J; Biernat, W; Polish Brain Metastasis, Consortium
BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: A population-based study 1-gen-2007 Musolino, A.; Bella, M. A.; Bortesi, B.; Michiara, M.; Naldi, N.; Zanelli, P.; Capelletti, M.; Pezzuolo, D.; Camisa, R.; Savi, M.; Neri, T. M.; Ardizzoni, A.